Gene Therapy for Alpha 1- Antitrypsin Deficiency — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Gene Therapy for Alpha 1- Antitrypsin Deficiency — Stella

Home/Alpha 1-Antitrypsin Deficiency/

View on ClinicalTrials.gov

Recruiting

Back to Alpha 1-Antitrypsin Deficiency trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

WCMC Department of Genetic Medicine, New York, New York

Key details

Phase

Early testing

Sponsor

Weill Medical College of Cornell University

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Enrollment target

~16 participants

Started

February 2025

Primary completion

April 2028

Age range

18 Years – 70 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.